2m 2m 2m 2m 2m 2m 2m
- $282.2MMarket Cap
- -61.92%1-Year Change
- Medical DevicesIndustry
CLEARPOINT NEURO (CLPT)
Key Performance
More- Earnings Score: 14
- Momentum Score: 50
- True Yield: N/A
- Financial Health Score: 5
Latest Research & News
Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.
10/13/2026, 5:49 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/22/2026
Company Profile
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Key Executives
- Joseph Michael Burnett
- Danilo D'Alessandro
- Jeremy Stigall
- Robert C. Korn
- Megan Faulkenberry
Current Ownership Distribution
- Institutions139.6M (74.46%)
- Mutual Funds44.8M (23.92%)
- Insiders3.0M (1.61%)
- Other0 (0.00%)